Tvardi Therapeutics (NASDAQ:TVRD) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) to a strong sell rating in a research report sent to investors on Saturday.

Other analysts also recently issued reports about the stock. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. BTIG Research restated a “buy” rating and set a $15.00 target price on shares of Tvardi Therapeutics in a report on Tuesday, July 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a report on Wednesday, July 8th. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Tvardi Therapeutics Stock Down 8.4%

Shares of TVRD stock opened at $2.93 on Friday. The stock has a 50-day simple moving average of $3.02 and a 200 day simple moving average of $3.48. The stock has a market capitalization of $27.48 million, a P/E ratio of -0.95 and a beta of 0.39. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08). On average, sell-side analysts anticipate that Tvardi Therapeutics will post -2.32 earnings per share for the current year.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $43,000. Headlands Technologies LLC acquired a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $80,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $92,000. Finally, Squarepoint Ops LLC purchased a new position in Tvardi Therapeutics during the 3rd quarter worth approximately $318,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.